Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > COMMENTARY
COMMENTARY
-
What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
-
Hot Products in 2013: New Drugs Likely to Jolt RA Treatment, Anticoagulant Markets
January 8, 2013
-
Counterfeit Drugs: Risks Lurking in Globalization
December 28, 2012
-
Can Japan Craft Its Own “Compassionate Use” System without Spoiling Drug Makers’ Development Drives?
December 7, 2012
-
Recent Announcements of Suspended Product Supplies Highlight Supply Risks Faced by Generic Drug Industry
November 27, 2012
-
Will Integration of Domestic Makers Be Enough for Sustainable Plasma Fractionation Operations?
November 16, 2012
-
Approval of Switch-OTC Epadel Puts Spotlight on Quality, Track Record of Pharmacists
November 9, 2012
-
Final Preparations Underway for Trial Run of Medical Database
September 25, 2012
-
Competition Getting Fiercer in COPD Drug Market
September 13, 2012
-
FY2013 Budget Expected to Have Positive Impact on Pharmaceutical and Medical Device Industries
August 30, 2012
-
Pharmaceutical Bar Coding Initiatives Spreading Among Western Countries
August 21, 2012
-
Government Shows Consideration towards Municipalities on IPV Price Issue
August 14, 2012
-
Challenges Emerging from Hiroshima: Improvement of Wholesalers' “Services of Convenience”
August 1, 2012
-
Integration of Advanced Healthcare System to Strengthen Linkage Between Development, Insurance, and Regulatory Approval
July 10, 2012
-
Major Generic Drug Makers Trying New Strategies to Boost Product Strengths
July 6, 2012
-
Gov’t to Support Development of Innovative Drugs of Japanese Origin through Drug Discovery Support Network
June 22, 2012
-
Discussions on Long-Listed Drugs Must Balance Interests of All Stakeholders
June 14, 2012
-
Supply of New Drugs Prior to NHI Price Listing to Increase as More Makers Target Drugs with Unmet Medical Needs
April 20, 2012
-
Fewer Takers, High Pass Rate in Nat’l Pharmacists’ Exam for 1st Graduates of Six-year Education System
April 5, 2012
-
Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 2
March 26, 2012
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…